Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

XPO1inhibition induces NCOR1-Dependent oxidative stress to suppress hepatocellular carcinoma

ABSTRACT: Hepatocellular carcinoma (HCC) remains a therapeutic challenge due to the limited efficacy of current systemic therapies. To identify potential novel therapeutic approaches, computational analysis of HCC datasets and drug screening were integrated, leading to the repurposing of hematological cancer drug selinexor (an XPO1 inhibitor) for HCC treatment. Functional studies revealed that XPO1 inhibition triggers oxidative stress and cell cycle arrest in HCC cells through nuclear sequestration of NCOR1, disrupting redox homeostasis through FOXK1-dependent transcriptional activation of genes associated with Reactive Oxygen Species (ROS). A genome-wide CRISPR-Cas9 screen further identified the KEAP1-NRF2 axis as a key determinant of sensitivity to XPO1 inhibition. Furthermore, high-throughput compound screening demonstrated that disulfiram, a clinically-used aldehyde dehydrogenase inhibitor, synergizes with XPO1 inhibitor through exacerbation of ROS accumulation. Collectively, these findings demonstrate the therapeutic repurposing of selinexor for HCC while uncovering its novel mechanism of action, establishing a predictive biomarker, and proposing an immediately translatable combination therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE318009 | GEO | 2026/06/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Discovery, Validation and Mechanistic study of XPO1 inhibition in the Treatment of Triple Negative Breast Cancer

Project description:Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with limited treatment options. This study investigates the potential of repurposing selinexor, an XPO1 inhibitor, as a novel therapeutic option for TNBC. By utilizing a computational drug repurposing approach, XPO1 inhibitors were identified to be preferentially sensitive in TNBC compared to other breast cancer subtypes and its efficacy validated in an independent patient dataset and across various TNBC cell lines. Using RNA-sequencing after longitudinal XPO1 inhibition in a panel of TNBC cell lines and western blotting, we reveal that XPO1 inhibitor induces TNBC cell death by inhibiting the NF-kB pathway through nuclear retention of NFKBIA, a key regulator of this pathway. These findings suggest that XPO1 inhibitors could be an effective targeted therapy for TNBC and paves the way for more personalized treatment strategies offering hope for better outcomes in TNBC patients.

2024-12-02 | GSE278241 | GEO

Targeting CDK4/6 impairs RB1/E2F activity to overcome the resistance to selinexor in Nature killer/T-cell lymphoma

Project description:XPO1 is frequently overexpressed in multiple hematological malignancies, highlighting the attractiveness of targeting XPO1 as a therapeutic strategy. However, the therapeutic potential of XPO1 inhibition in NKTL was still not well documented. Here, we demonstrated that XPO1 is highly expressed in NKTL and is correlated with poor prognosis, suggesting that XPO1 is a potential target in NKTL. In addition, we identified YY1 as a transcriptional factor that bound to XPO1 promoter to activate its expression. Functional studies revealed that pharmacological inhibition of XPO1 using selinexor effectively blocks CDK4/6-pRB-E2F-c-Myc signaling, resulting in cell cycle arrest and apoptosis in sensitive cells. Transcriptomic analysis identified that dysfunction in cell cycle machinery may contribute to selinexor resistance, as resistant cells restore the expression of cycle-related genes to evade cell death. High-throughput screening utilizing a panel of 130 cell cycle inhibitors identified CDK4/6 inhibitors as sensitizers to selinexor in resistant cells. Mechanistically, the combination of CDK4/6 inhibitors and selinexor led to an enhanced inhibition of pRB-E2F-c-Myc signaling. Additionally, compassionate use of selinexor in combination with chemotherapy (gemcitabine, oxaliplatin) in three Refectory/Relapsed (R/R) NKTL patients achieved favorable clinical outcomes. Our data unveil a novel mechanism by which XPO1 inhibition blocks CDK4/6-pRb-E2F-c-Myc signaling, providing a rationale for the combination of CDK4/6 with XPO1 inhibitors for NKTL treatment.

2025-05-13 | GSE230615 | GEO

Deep proteomic and phosphoproteomic profiling of neuroblastoma treated with XPO1 inhibitor Selinexor

Project description:Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1 that shuffles cargo proteins with a nuclear export sequence, many of which are essential for cancer growth and cell maintenance, from the nucleus to the cytosol. We systematically tested the effect of selinexor against neuroblastoma cells in vitro and in vivo and used a proteomics screening approach to interrogate unknown mechanisms of action. We found that selinexor induces its cytotoxic effects in neuroblastoma through the nuclear accumulation of p53. By combining selinexor with an aurora kinase inhibitor, alisertib that is already in clinical use for neuroblastoma, we show that p53-mediated lethality can be further augmented supporting clinical testing of this drug combination against neuroblastoma

2023-03-11 | PXD026454 | Pride

Spatial proteomics of selinexor, MK-2206 and combination response in AML cells

Project description:In order to characterize the dynamics of proteins between different cellular compartments in response to selinexor (XPO1 inhibitor), MK-2206 (Akt inhibitor) an the combination i AML cells, we treated MV4-11 and PL-21 cells for 6 hours with DMSO, 1 uM selinexor, 1 uM MK-2206 or the combination. Each condition was performed in 4 biological bio-reps.

2022-08-07 | PXD033527 | Pride

Proteomic study of Selinexor alleviating bleomycin-induced pulmonary fibrosis

Project description:Selinexor is an orally bioavailable, small-molecule selective inhibitor of nuclear export protein that has been approved for the clinical treatment of relapsed or refractory multiple myeloma. At present, some studies have found that Selinexor can play an anti-inflammatory role in sepsis. We found that Selinexor, a selective inhibitor of XPO1, can alleviate bleomycin-induced pulmonary fibrosis in mice in our research work, but the specific mechanism is still unclear. After Selinexor treatment of bleomycin-induced pulmonary fibrosis in mice, we detected some differentially expressed proteins through proteomics, which may be the key mechanism of alleviating pulmonary fibrosis.

| PXD044259 |

RNA sequencing of neuroblastoma cells treated with selinexor or with XPO1 knockdown

Project description:The study objective was to profile the transcriptomic changes in neuroblastoma IMR5 cells following treatment with selinexor for 24 hours or XPO1 knockdown at 72 hours.

2025-05-19 | GSE178937 | GEO

Disulfiram inhibits bacterial growth by inducing zinc-dependent reactive oxygen species

Project description:With the growing threat posed by emerging drug-resistant bacteria, the discovery of new antibiotics and the exploration of additional antimicrobial mechanisms of medicines currently used in the clinic are urgent. In this study, we found that disulfiram, a drug used for the treatment of alcohol addiction, inhibited the growth of multiple bacteria and quickly inhibited the growth of E. coli. When combined with kanamycin or polymyxins in vitro, disulfiram could augment the bactericidal effect against E. coli or A. baumannii. When combined with colistin in vivo, disulfiram also protected against murine E. coli infection. Disulfiram inhibited the motility of E. coli but did not change its length morphologically. Transcriptomic analysis revealed that disulfiram-treated E. coli presented an oxidative stress pattern and zinc-related transcriptomic changes. Moreover, the bacteriostatic effect of disulfiram on E. coli and S. aureus could be fully prevented by the ROS scavenger NAC. In addition, zinc ions increased ROS levels and further suppressed bacterial growth, whereas zinc chelators suppressed ROS and restored the growth of both E. coli and S. aureus. This study reveals that disulfiram inhibits bacterial growth by inducing zinc-dependent intracellular reactive oxygen species (ROS). This bacteriostatic effect can be reversed by ROS scavengers or zinc chelators, highlighting a previously uncharacterized antimicrobial mechanism for disulfiram.

2025-06-05 | GSE299097 | GEO

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

Project description:Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as selinexor, an inhibitor of XPO1-mediated nuclear export. Through quantitative nuclear protein profiling and phospho-kinase arrays, we identified potential mode of actions of this combination, including interference with ribosome biogenesis and inhibition of pro-survival kinase PRAS40. Furthermore, by assessing global protein levels changes, FADS2, a key enzyme regulating fatty acids synthesis, was found down-regulated after proteasome inhibition. Interestingly, SC26196, an inhibitor of FADS2, synergized with carfilzomib. Finally, to identify further combinational options, we performed high-throughput drug screening and uncovered novel drug interactions with carfilzomib. For instance, cyclosporin A, a known immunosuppressive agent, enhanced carfilzomib’s efficacy in vitro and in vivo. Altogether, these results demonstrate that carfilzomib and its combinations could be repurposed for LPS clinical management.

2020-09-28 | PXD021001 | Pride

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

2020-09-28 | PXD020906 | Pride

Validation of a non-oncogene encoded vulnerability to Exportin 1 inhibition in pediatric renal tumors

Project description:We identified XPO1 as an aberrantly activated, non-oncogene encoded targetable vulnerability in pediatric renal tumors (Wilms and malignant rhabdoid tumor [MRT]) using OncoTarget, a Master Regular-based precision cancer medicine tool. We demonstrate significant anti-tumor activity of selinexor and eltanexor, two selective XPO1 inhibitors, in patient derived xenograft mice models of Wilms and MRT, and report on a case of successful treatment of a pediatric cancer patient.

2022-03-09 | GSE198000 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data